Clinical trial · Observational
Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.
NCT00759382CI-TRIAL-00053443unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary aim of this non interventional study is to assess the independent prognostic role on overall survival of primary tumour 18F-FDG uptake value (SUVmax) measured on 18fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in patients with non-metastatic non-small cell lung cancers treated with curative intent, taking into account the other conventional prognostic factors (performance status, age, sex, disease stage).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- I
- description
- Patients with non-small cell lung carcinoma treated with curative intent
Primary outcomes (1)
- measure
- Survival
- timeFrame
- Survival will be dated from the date of PET scan
Secondary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- Period between the date of PET scan and the date of first progression or death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically demonstrated NSCLC * Stage I-III treated by curative treatment by surgery with or without chemotherapy (induction or adjuvant) or by chemoradiotherapy * Inoperable patients treated by exclusive radiotherapy * A whole-body (skull base to mid thighs) FDG-PET or a combined FDG-PET/CT on a dedicated machine, performed before any anticancer treatment * FDG-PET or combined FDG-PET/CT has to be previously standardised according to the procedure described in appendix IV * Written informed consent * Accessibility to follow-up * Age \> 18 years Exclusion Criteria: * Prior anticancer treatment (surgery, radiotherapy or chemotherapy) * Stage IV NSCLC * A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumour (more than 5-year disease free interval) * Uncontrolled diabetes mellitus (fast glycaemia above 130 mg/dl) * Pregnancy and lactating woman * Unavailability to send a copy of the PET or PET-CT (DICOM format) to the data centre
References
Publications (0)
Data not yet available
No reference posted for this study.